Activity 1: Overview of the viral hepatitis problem

Journal of Family Practice

Volumn 59, Issue SUPPL. 4, 2010, Pages

  Lok, Anna S F ^a   Kim, W Ray ^b   El Serag, Hashem B ^c   Maddrey, Willis C ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B VACCINE; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DISPARITY; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MASS SCREENING; PATIENT COMPLIANCE; PUBLIC HEALTH PROBLEM; SEXUAL TRANSMISSION; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VETERAN; VIRUS CARRIER; VIRUS TRANSMISSION; ADULT; ARTICLE; COST OF ILLNESS; FEMALE; HETEROZYGOTE; MALE; MIDDLE AGED; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; CARRIER STATE; COST OF ILLNESS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

EID: 77951293110     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Centers for Disease Control and Prevention. Division of Viral Hepatitis. Statistics and Surveillance. Disease burden from viral hepatitis A, B, and C in the United States. http://www.cdc.gov/hepatitis/PDFs/disease-burden.pdf. Accessed October 14, 2009.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
3. Cohen C, Evans AA, London WT, et al. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 2008;15:12-13. (Pubitemid 350243575)
4. Edlin B. Five million Americans infected with the hepatitis C virus: a corrected estimate. Presented at: American Association for the Study of Liver Diseases 56th Annual Meeting; November 11-15, 2005; San Francisco, CA. Hepatology. 2005;42:213A.
5. Kuehn BM. Silent epidemic of viral hepatitis may lead to boom in serious liver disease. JAMA. 2009;302:1949-1950, 1954.
6. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ. 2009;58:1-27.
7. Kim WR, Benson JT, Therneau TM, et al. Changing epidemiology of hepatitis B in a U.S. community. Hepatology. 2004;39:811-816. (Pubitemid 38337662)
8. Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander populations - New York City, 2005. MMWR Morb Mortal Wkly Rep. 2006;55:505-509.
9. AIDS Treatment Data Network. Simple facts project: HCV and HIV co-infection. http://www.atdn.org/simple/coinf.html. Accessed October 14, 2009.
10. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41:88-96.
11. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999;31(suppl 1):88-91. (Pubitemid 30002698)
12. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150:104-110.
13. Centers for Disease Control and Prevention. Hepatitis B FAQs for Health Professionals. http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm. Accessed December 11, 2009.
14. Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed October 14, 2009.
15. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
16. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686.
17. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009;49:1838-1846.
18. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124-134. (Pubitemid 47057730)
19. El-Serag H. When good treatments fail: the disconnect between efficacy and effectiveness. Presented at: The Dawn of a New Era: Transforming Our Domestic Response to Hepatitis B & C; September 10-11, 2009; Washington, DC.
20. Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750-1755.
21. Shehab TM, Orrego M, Chunduri R, et al. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol. 2003;98:639-644. (Pubitemid 36348538)
22. Bini EJ, Bräu N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772-1779.
23. Shehab TM, Fontana RJ, Oberhelman K, et al. Effectiveness of interferon a 2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol. 2004;2:425-431.
24. Trevisani F, De NS, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734-744.
25. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
26. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
27. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
28. Weinbaum, CM, Williams I, Mast EE, et al; Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20.
29. Davila JA, Morgan RO, Richardson PA, et al. Utilization of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology; 2010. [Epub ahead of print.]
30. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166.